Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor announced that Phase 1 study results for XmAb819 in advanced clear cell renal cell carcinoma were accepted for a proffered paper oral presentation at the ESMO 2026 Congress. The presentation will highlight expansion-cohort results to determine the recommended Phase 3 dose, with a pivotal study of XmAb819 monotherapy planned to begin in 2027.
Key figures
- Drug Name
- XmAb819
- Phase Of Trial
- Phase 1
- Nct id
- NCT05433142
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.